A comparison of phase II study strategies

Clinical Cancer Research

Volumn 15, Issue 19, 2009, Pages 5950-5955

  Hunsberger, Sally ^a   Zhao, Yingdong ^a   Simon, Richard ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL RESEARCH; INTERMETHOD COMPARISON; LUNG CANCER; MATHEMATICAL MODEL; PANCREAS CANCER; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG DESIGN; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349671467     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3205     Document Type: Article

References (20)

1. Korn EL, Simon R. Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials. J Clin Oncol 1993;11:794-801, PubMed. (Pubitemid 23105690)
2. Green S, Benedetti J, Crowley J. Clinical trials in oncology. Cambridge: Chapman & Hall; 1997.
3. Dixon DO, Simon R. Sample size considerations for studies comparing survival curves using historical controls. J Clin Epidemiol 1988;41: 1209-1213, PubMed. (Pubitemid 19036523)
4. Makuch RW, Simon RM. Sample size considerations for nonrandomized comparative studies. J Chronic Dis 1980;33:175-181, PubMed.
5. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-3516, PubMed. (Pubitemid 46243495)
6. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946-3952, PubMed. (Pubitemid 46630743)
7. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-3783, PubMed. (Pubitemid 41095218)
8. Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002;20:1512-1518, PubMed. (Pubitemid 34260530)
9. Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer 2001;92:569-577, PubMed.
10. Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995;6: 129-132, PubMed.
11. Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005;23:7199-7206, PubMed. (Pubitemid 46260307)
12. Simon RM, Steinberg SM, Hamilton M, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001;19:1848-1854, PubMed. (Pubitemid 32230888)
13. Ratain MJ, Stadler WM. Clinical trial designs for cytostatic agents. J Clin Oncol 2001;19: 3154-3155, PubMed.
14. Ratain MJ, Eisen T, StadlerWM, et al. Phase II placebo- controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:2505-2512, PubMed.
15. Inoue LY, Thall PF, Berry DA. Seamlessly expanding a randomized phase II trial to phase III. Biometrics 2002;58:823-831, PubMed.
16. Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994;50:1029-1041, PubMed.
17. Proschan MA, Hunsberger SA. Designed extension of studies based on conditional power. Biometrics 1995;51:1315-1324, PubMed.
18. Barthel FMS, Sydes M, et al. Speeding up the evaluation of new agents in cancer. J Natl Cancer Inst 2008;100:1204-1214, PubMed.
19. Goldman B, LeBlanc M, Crowley J. Interim futility analysis with intermediate endpoints. Clin Trials 2008;5:14-22.
20. Rubinstein LV, Gail MH, Santner TJ. Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis 1981;34:469-479 PubMed doi:10.1016/0021-9681(81) 90007-2.